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SUMMARY
To inform current and future vaccination strategies, we describe the seroepidemiology of hepatitis
B virus (HBV) infection in ten representative European countries using standardized serology
that allowed international comparisons. Between 1996 and 2003, national serum banks were
compiled by collecting residual sera or by community sampling; sera were then tested by each
country using its preferred enzyme immunoassays and testing algorithm, and assay results were
standardized. Information on current and past HBV vaccination programmes in each country
was also collected. Of the ten countries, six reported low levels (<3%) of antibodies against HBV
core antigen (anti-HBc). Of the eight countries testing for HBV surface antigen (HBsAg), the
highest prevalence was reported in Romania (5.6%) and in the remaining seven countries
prevalence was <1%. Universal HBV vaccination programmes had been established in seven
countries as recommended by the World Health Organization, but the seroprevalence of
antibodies against HBsAg (anti-HBs) was lower than the reported vaccine coverage in three
countries. Regular serological surveys to ascertain HBV status within a population, such as
reported here, provide important data to assess the need for and to evaluate universal HBV
vaccination programmes.
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INTRODUCTION
Infection with hepatitis B virus (HBV) is a problem of
global public health importance. The failure of in-
dividuals to clear HBV leads to a chronic infection,
characterized by carriage of the HBV surface antigen
(HBsAg), a marker of infectivity as well as possible
progression to end-stage hepatic diseases such as cir-
rhosis or primary hepatocellular carcinoma [1].
The Regional Office for Europe of the World
Health Organization (WHO) has estimated that in
Europe each year one million people become infected
with HBV, and of these 90 000 evolve to a chronic
carrier state and more than 22 000 die of cirrhosis
or hepatocellular carcinoma [2]. The prevalence of
HBsAg, which is influenced primarily by the age at
infection, has been used to categorize endemicity as
high (o8%), intermediate (2–8%), low (<2%) [3] or
very low (<0.5%) [4]. In Europe, there are wide vari-
ations in reported HBsAg carriage, increasing west to
east and north to south [3]. This geographical vari-
ation is reflected in the estimated mortality from
cirrhosis and hepatocellular carcinoma due to HBV,
with about 200 attributable deaths annually in north-
western Europe compared to nearly 19 000 in central
and eastern Europe [2].
HBV is a possible candidate disease for elimination
and ultimately eradication as the reservoir for HBV
is entirely human and highly efficacious preventative
vaccines are available [5]. In 1991, the WHO called on
all countries to introduce universal HBV vaccination
by 1997 [6]. By the end of 2004, universal HBV vac-
cination programmes were in place in 43 of the 52
countries in the WHO European region [7]. Some
countries in northern and western Europe, where
endemicity is low, have not implemented universal
HBV vaccination programmes [4] but rather selective
immunization programmes [8, 9] targeting migrant
populations and at-risk groups [10, 11].
Serological surveillance is a vital tool for assessing
the burden of infection and thus the need for a vacci-
nation programme as well as the evaluation of such
programmes once they are in place. The use of an
algorithm testing for HBsAg as well as antibodies
to surface (anti-HBs) and core (anti-HBc) antigens
enables serological studies to estimate the prevalence
of carriers, resolved infection and vaccinated indi-
viduals in a population [3]. Thus, serological data
can supplement HBV disease surveillance data, which
are limited because of underreporting of acute and
chronic cases, the long incubation between infection
and disease as well as the large proportion of asymp-
tomatic acute cases, especially in children.
The European Sero-Epidemiology Network
(ESEN2), based on the previous ESEN project [12],
was established in 2001 with the aim of standardizing
serological surveillance to eight vaccine-preventable
diseases, of which one was HBV infection, in 22
European countries [13]. Variations in antibody titres
have been reported between laboratories, even those
using the same assay [14, 15]. Thus, the standardiza-
tion of assay results was essential to allow inter-
national comparisons of HBV serology. We present
the comparison of HBV seroepidemiology in the ten
participant countries in order to describe the epi-
demiology of HBV infection in Europe in relation
to vaccine policy, to inform the development of the
most appropriate control measures and to evaluate
vaccination programmes in place.
METHODS
Serum survey collection
As part of ESEN2, ten countries undertook testing
for HBV antibody and antigens in sera specimens
collected between 1996 and 2003 (Table 1). The sera
were obtained either by residual sera collected dur-
ing routine laboratory testing (6/10 countries) or by
population-based random sampling (4/10) (Table 1).
Ethical approval was sought from the appropriate
national authorities for all collections.
Sera were evenly distributed between males and fe-
males and were geographically representative of each
country. Project guidelines recommended that >3000
samples should be tested from all age groups, of which
two-thirds were from those aged <20 years [12]. Sera
were collected in all age groups except in Belgium
(only those aged <20 years), Germany (from 17 to
o60 years) and Luxembourg (from 4 to o60 years)
(Table 2). Furthermore, smaller than recommended
sample sizes were collected in the Czech Republic
(2644 samples tested), Ireland (2535) and Romania
(1338) (Table 2).
Organizational analysis
In March 2002, a standardized questionnaire re-
questing historical information regarding the HBV
vaccination programmes was sent to all national
representatives. Reported infant HBV vaccination
coverage was updated with data reported to the
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WHO, accessed from the ‘Health For All ’ database in
August 2007.
Assay standardization
The methodology and results of the qualitative and
quantitative standardization of the antibody and
antigen results have been described in detail elsewhere
[14, 16]. In brief, the designated reference centre
(Hellenic Centre for Disease Control, Athens, Greece)
prepared a panel of 172 sera, which were tested using
the Abbott AxSYM system (Abbott Laboratories,
Abbott Park, IL, USA) for three markers of HBV
infection or vaccination: anti-HBs, anti-HBc and
Table 2. Age-specific seroprevalence of anti-HBc-positive and HBsAg-positive samples in ten ESEN2 countries,
1996–2003






















Belgium* 1.3 0.7 1496 1.1 0.7 1175 1.9 0.6 321 — — —
Czech Republic# 2.5 0.3 2644 0.2 0.3 975 1.9 0.2 1148 8.3 0.8 521
Germany* 6.0 — 6748 — — — 2.9 — 2690 8.2 — 4058
Italy 5.6 0.6 3522 1.9 0.1 1655 4.3 0.9 1266 18.8 1.5 601
Luxembourg* 2.9 — 2678 0.9 — 1086 4.3 — 1031 4.1 — 561
Romania 20.5 5.6 1259 9.4 5.1 630 23.6 7.6 276 38.0 5.1 353
Slovakia 10.5 0.6 3569 7.1 0.1 1623 10.6 0.9 1270 18.6 1.5 676
Targeted immunization
Finland 2.7 0.2 3083 1.7 0.2 1281 2.8 0.3 1200 4.3 0.2 602
Ireland 1.7 0.1 2535 1.0 0.0 877 1.7 0.1 1194 2.8 0.2 464
The Netherlands 1.7 0.1 6750 0.3 0.0 1691 1.4 0.2 1810 2.6 0.2 3249
* Samples collected from limited age ranges : Belgium 1–20 years ; Germany >16 years ; and Luxembourg >3 years.
# Czech Republic compiled the serum bank at the same time as the introduction of universal infant immunization (2001).
Table 1. Childhood vaccination policies for hepatitis B, national serum bank collection and serological testing
algorithms employed in the ten participant countries in ESEN2
Childhood HBV
vaccination programmes


















Belgium Universal 1999 11–12 Residual 2002/2003 3/4 + + Anti-HBc+
Czech Republic Universal 2001 12 Population 2001 0 + + Anti-HBc+
Germany Universal 1995 9–17 Residual 1998 3 + + —*
Italy Universal 1991 12 Residual 1996 5 + + Anti-HBc+
Luxembourg# Universal 1996 12 Population 2000/2001 4/5 + +$ —
Romania Universal 1995 9 Residual 2002 7 + + Anti-HBc+
Slovakia Universal 1998 12 Population 2002 6 + + Anti-HBc+
Finland Targeted — — Residual 1997/1998 — + — Anti-HBc+
Ireland Targeted — — Residual 2003 — + — Anti-HBc+
The Netherlands Targeted — — Population 1995/1996 — + — Anti-HBc+
* Years elapsed between introduction of vaccination programme and serum bank collection.
# All anti-HBc samples were tested for HBsAg but data unavailable.
$ All samples tested for anti-HBs antibody, of which only positives were tested for anti-HBc antibodies.
HBV seroepidemiology in Europe 963
HBsAg. The panel included negative, equivocal, low
and high positive anti-HBs and anti-HBc antibody
titres, thereby enabling the quantitative standardiz-
ation of the antibody responses. In contrast, only
qualitative standardization of HBsAg results was
performed [14].
These panels were distributed to participant labora-
tories where they were tested for anti-HBs, anti-HBc
and HBsAg with the enzyme immunoassay normally
used by the participating laboratory [14]. For each
antibody marker of HBV infection (i.e. anti-HBs and
anti-HBc), national results of testing the reference
panel were plotted against those of the reference
centre and a regression was performed. The equation
of the line-of-best-fit was used as a standardization
equation so that local titres could be converted to
standard titres. The standardizations of the assays
were evaluated quantitatively by determining the fit of
the equation using R2 (coefficient of determination)
and qualitatively by assessing the level of concordance
in identifying positive, negative and equivocal results
[14, 16].
In two countries (Germany and The Netherlands),
the serum banks had been tested over a year before
the distribution of the reference panel. A method of
back-standardization, described in detail elsewhere
[16], was performed in these countries in order to
standardize their results to project units. In brief,
about 150 sera, representative of the different defined
statuses (e.g. resolved infection, vaccinated) were ran-
domly selected from the national serum bank and for-
warded to the reference centre for testing for the three
serological markers of HBV infection. A regression
analysis, as described above, was performed on the
two sets of data in order to obtain the appropriate
standardization equation [14].
Main serum bank testing
Each national serum bank was tested using the same
validated assay as was used for the reference panel.
For the anti-HBc and anti-HBs antibody results, the
country-specific standardization equations were used
to convert the local quantitative results of the serum
survey into standardized reference laboratory units.
The reference laboratory cut-offs were used to re-
classify qualitatively the standardized quantitative re-
sults as negative, equivocal or positive. As testing of
the reference panel for HBsAg showed 100% con-
cordance [14], the HBsAg result was taken as that re-
ported by the national participant.
National HBV testing algorithms
The HBV testing algorithms employed often reflected
whether a universal childhood HBV vaccination pro-
gramme was in place in those countries (Table 1).
Most countries with a vaccination programme tested
all samples for anti-HBc and anti-HBs, and then went
on to test anti-HBc-positive samples for HBsAg.
Germany tested all samples for anti-HBc and anti-
HBs, but data regarding HBsAg were unavailable due
to insufficient volumes of sera for back-standardiza-
tion. Luxembourg tested all samples for anti-HBs,
and then tested anti-HBs-positive samples for anti-
HBc, but no testing for HBsAg was undertaken.
The HBV testing algorithm for countries without
a universal childhood vaccination programme was
to test all samples for anti-HBc, and then only test
anti-HBc-positive samples for HBsAg (Table 1). In
these countries, all anti-HBc negative samples were
assumed to be anti-HBs negative as the level of
vaccination was very low.
Although the participant countries employed dif-
ferent HBV testing algorithms, we were able to cate-
gorize all sera into four groups: no history, vaccinated
(only anti-HBs positive), resolved HBV infection
(anti-HBc and anti-HBs positive) and acute infection
or chronic carriers (anti-HBc positive and HBsAg
positive). It should be noted that the testing algo-
rithms employed would have misclassified as ‘no
history’thosewhowerechroniccarriersinLuxembourg
as well as successfully vaccinated individuals in
Finland, Ireland and The Netherlands.
RESULTS
At the time of the sera collections, three countries
(Finland, Ireland, The Netherlands) had only a
targeted vaccination programme of at-risk individuals
(e.g. men who have sex with men, or injecting drug
users) as well as screening pregnant women for
HBsAg (Table 1). The remaining seven countries had
introduced universal HBV immunization of infants,
and all had included recommendations for adolescent
catch-up vaccination, ranging from age 9 years
(Romania) to age 17 years (Germany). In six of these
seven countries, the main serum banks were collected
after the introduction of the mass infant immuniza-
tion, and one (Czech Republic) at the same time
(Table 1).
Of the ten participant countries, the highest pre-
valence of previous exposure to HBV infection (i.e.
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anti-HBc positive) was observed in Romania, where
20.5% of sera were anti-HBc positive (Table 2). The
percentage exposed increased with age; from 9.4% in
children (1–15 years) to 38.0% in older adults (o40
years) (Table 2). Similarly, the prevalence of HBsAg
was highest in Romania (5.6%), although there was
no increase in prevalence by age group (x2=2.7,
P=0.25). The seroprofile for Romania demonstrates
that although the reported coverage of infants with
HBV vaccination was high (>95% of infants), a large
percentage of children had no markers of vaccination
(Fig. 1). For example, the reported vaccine coverage
of those aged 3–4 years was 98%, but only 63% had
serological evidence of vaccination (i.e. anti-HBc
negative and anti-HBs positive). Just under 4% of
this age group had been exposed to HBV infection,
of which a third (or 1% of the total) were HBsAg
positive (Fig. 1).
Of the remaining nine countries, only Slovakia
showed previous exposure to HBV infection in the
population >10% (10.5%). The proportion of anti-
HBc-positive samples increased with age, from 7.1%
in children to 18.6% in older adults (Table 2).
The proportion of HBsAg-positive individuals in the
population was <1% (0.6%) and similarly increased
with age, from 0.1% in children to 1.5% in older
adults (x2=15.2, P<0.001) (Table 2). Children aged
f4 years would have been targeted by the HBV vac-
cination of infants introduced with a high reported
coverage (>95%), and among 1-year-olds 85% were
anti-HBs positive (Fig. 1). In contrast, despite the
introduction of a catch-up vaccination campaign of
12-year-olds,<15% of adolescents in the 12–15 years
age group had serological evidence of vaccination
(Fig. 1).
In Italy, the overall prevalence of past exposure to
HBV infection was 5.6%, with much higher preva-
lence of anti-HBc being observed in those aged o40
years (18.8%) than in the younger adult age groups
(1.9% and 4.3% respectively) (Table 2, Fig. 1). The
carriage of HBsAg also increased with age, from
0.1% in children to 1.5% in older adults (x2=17.8,
P<0.001) (Table 2). HBV vaccination of both infants
and adolescents was well implemented in Italy as
>80% of recently targeted age groups (i.e. 1–3 and
13–15 years) were anti-HBs positive.
In Germany, sera were collected from adults only.
Past exposure to hepatitis B was 6.0%, and as in Italy,
higher anti-HBc was observed in those aged o40
years (8.2%) than in the younger adult age groups
(2.9%) (Table 2, Fig. 1). No HBsAg data were
reported from Germany, but the proportion of anti-
HBc positive-/anti-HBs-negative samples (some of
which would have been HBsAg positive) increased
with age, from 0.7% (19/2680) in younger adults to
1.5% (67/6058) in older adults (x2=11.47, P<0.001).
Of the participants in Germany targeted by the
vaccination recommendation implemented in 1995
(17–20 years age group at the time of the serum col-
lection), only 9.6% were anti-HBs positive (Fig. 1).
The percentage of the population with a past
exposure to HBV infection was <5% in the remain-
ing six countries (Belgium, Czech Republic, Finland,
Ireland, Luxembourg, The Netherlands), ranging
from a minimum of 1.7% in Ireland and The
Netherlands to 2.9% in Luxembourg (Table 2). The
age-specific prevalence of past infection remained
<5% even in the oldest age groups except in the
Czech Republic where 8.3% of older adults (i.e. o40
years) had serological evidence of past exposure to
HBV infection.
In Belgium, where only samples from those aged
<20 years were tested, nearly 80% of the youngest
children (i.e. <4 years) were anti-HBs positive, al-
though coverage was reported as 60% in this age
group. Levels of anti-HBs in those aged 11–12 years
targeted by the catch-up recommendations were much
lower, but reached 70–80% in those aged 14–15 years
(Fig. 1). A large proportion of children aged between
4 and 11 years expressed serological markers of
vaccination, many of whom would not have been
targeted by an HBV vaccination campaign. In
Luxembourg, not only was there an important
percentage of children with serological markers of
HBV vaccination in age groups not targeted by HBV
vaccination, but also in those age groups that were
targeted by HBV vaccination, the proportion of
children with serological markers of vaccination was
much higher than the reported coverage of 49% in
4-year-olds (Fig. 1).
No universal HBV vaccination policies were in
place in Finland, Ireland and The Netherlands
(Table 1) and in these countries levels of surface
antigen carriage were lower than countries with
universal programmes (Table 1). In children, HBsAg
carriage was reported to be 0% in Ireland and The
Netherlands and 0.2% in Finland. In Finland, car-
riage in children was higher than in Italy and Slovakia
(0.1% respectively) and in young adults was higher
than in the Czech Republic (0.2%, Table 1).
No gender differences were observed in any of the
countries for past exposure to HBV (i.e. anti-HBc
HBV seroepidemiology in Europe 965
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Fig. 1. HBV seroprofiles showing reported HBV vaccine coverage in infants (%–––%) and as a histogram the prevalence of samples tested with no history (%), anti-HBs-
positive only ( ), anti-HBc positive ( ) and HBsAg positive (&)* in ten ESEN2 countries, 1996–2003 (* in Germany these samples were anti-HBc positive and anti-HBs
negative). Universal infant vaccination programme: Belgium, Czech Republic, Germany, Italy, Luxembourg, Romania, Slovakia. Targeted vaccination programme:


















positive) in young adults (aged 16–39 years). Stat-
istically significant gender differences in HBsAg car-
riage were reported only Romania (9.9% males,
2.9% females ; x2=6.27, P=0.01). In the five coun-
tries with testing algorithms providing serological evi-
dence of vaccination, young women were more likely
to be anti-HBc negative and anti-HBs positive than
men in Germany and in Slovakia; although only in
Germany would any of this age group (17–20 years)
have been targeted by a catch-up immunization pro-
gramme.
DISCUSSION
We report for the first time a study comparing HBV
seroepidemiology in ten European countries, in which
possible inter-assay and inter-laboratory variations
have been controlled for by a standardization pro-
cedure [14, 16]. Thus, international comparisons of
the epidemiology of HBV and in particular the per-
formance of national immunization, control and pre-
vention programmes can be made. The ten countries
participating in this study were not randomly selected
and they were representative of Europe in terms
of geography, vaccination policies and HBV epidemi-
ology [2, 3].
Of the participant countries, the burden of infection
was highest in Romania where prevalence of HBsAg
carriage (5.6%) was in the intermediate range of
endemicity (i.e. 2–8%). Levels of carriage were very
much lower in those age groups targeted by the vac-
cination programme than in those immediately older.
However, despite the universal childhood vaccination
programme, there is evidence of ongoing transmission
of HBV in younger birth cohorts and the reported
coverage is much higher than indicated by the sero-
survey. In Slovakia and Italy, we have presented
serological evidence of the impact of the childhood
vaccination programmes as there was high prevalence
of anti-HBs in targeted birth cohorts. However, the
evaluation of HBV vaccination programmes is best
done by a comparison of the prevalence of vaccinated
individuals at different time-points, as age and cohort
effects can contribute to changes in the prevalence of
individuals with past history of infection [17, 18].
In three countries (Italy, Romania, Slovakia), the
proportion serologically identified as vaccinated was
lower than the coverage reported in infants. This may
be accounted for in older age groups as antibody de-
cay following vaccination has been shown to be rapid
within the first year, declining more slowly thereafter
[19, 20]. Anamnestic responses, conferring immunity
to HBV infection, have been reported in individuals
with low or undetectable anti-HBs [21, 22], and a re-
port by a European consensus group recommended
that no booster doses for immunocompetent children
and adolescents [23]. Thus, differences in the reported
vaccine coverage and observed prevalence of vacci-
nated individuals may be of minimal public health
importance if vaccine coverage estimates are accurate,
which may not be so for all countries. In Belgium, the
prevalence of those with serological evidence of vac-
cination was higher than the coverage reported for
many ages, this might be because national coverage
was not always measured annually (H. Theeten,
personal communication). In Romania, discrepancies
between reported vaccine coverage and observed
serological correlates of protection were noted not
only for HBV, but also for other infections such as
measles [24].
Routine immunization of infants will eventually
result in a community with a broad-based immunity.
However, in many European countries, most infec-
tion occurs in young adults so that a stand-alone
infant immunization programme will take several
decades to eliminate HBV infection in the community
[3]. Many European countries, and all the countries
with a childhood vaccination programme participat-
ing in this study, have included a catch-up component
of older children and adolescents in order to more
quickly eliminate the infection from the community
[4]. The official catch-up policy in adolescents varied
from a recommendation to vaccinate, as in Germany,
to a campaign entailing mandatory vaccination as in
Italy [25, 26]. In three of the five countries (Germany,
Slovakia, Romania), adolescents appear to have been
poorly targeted by these catch-up campaigns as
evinced by the low proportion of anti-HBs positives in
this age group. These findings highlight the difficulties
in targeting such a population [25, 27].
Countries with a targeted rather than a universal
HBV vaccination programme have cited their very-
low HBV endemicity to justify their policy [7]. In
this study, the lowest overall prevalence of HBsAg
carriage was reported in the three countries with
targeted HBV vaccination programmes, although
similar prevalence of HBsAg carriage was reported in
the Czech Republic where an immunization campaign
had been recently implemented. Within Europe, the
migration of individuals from high- to low-endemicity
countries is having an impact on HBV [11, 28]. Tar-
geted programmes require continued refining and
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improved immunization options to ensure good
coverage in at-risk groups [11]. In The Netherlands,
an additional programme targeting children with
at least one parent coming from a middle- or high-
endemic country was introduced in 2003 (H. de
Melker, personal communication). Nonetheless, the
difficulties of implementing targeted vaccination pro-
grammes was one of the reasons for the change in
vaccination policy recently announced in Ireland [29]
and is cited by those advocating the introduction of a
universal programme [28, 30].
There are some limitations to our study. Two
countries did not provide HBsAg testing data
(Germany, Luxembourg), which meant that HBsAg-
positive samples could not be identified. In Germany,
we reported a prevalence of 1.3% (86/6748) anti-
HBc-positive and anti-HBs-negative samples which
represent both HBsAg carriers as well as isolated
anti-HBc. In the original study, a mean weighted
prevalence of HBsAg carriage of 0.6% was reported
[31]. The ‘ isolated anti-HBc’ are individuals whose
anti-HBs response may have waned, have an occult
chronic HBV infection without detectable HBsAg or
represent a false-positive reaction [32]. Such samples,
although they represent a minority of samples in the
sera collections reported here, have been categorized
as evidence of a past infection.
Another limitation is that we compared HBV
seroepidemiology between countries who compiled
serum banks either by residual sera collection or
community sampling. Community-based surveys of
HBV infection are recommended, as the results
are more representative and can be generalized to
the population [33]. However, in schoolchildren in
Australia, the HBV seroprevalence estimated from
residual sera or probability sampling was similar [34].
Other serological studies conducted as part of ESEN2
also did not report any correlation between reported
seroprevalence and methods of sera collection [35].
We have demonstrated the utility of serological
surveillance in assessing the need for HBV vacci-
nation programmes and their contribution to the
evaluation of such programmes where they have been
implemented. Serological surveillance, when under-
taken in a coordinated and standardized manner
and interpreted in the context of data of vaccination
programmes and vaccination coverage has provided
valuable information for the comparative evaluation
of vaccine programmes internationally. Therefore,
such initiatives should play an important role in
public health in Europe.
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